Recent investigations have converged on the overlap of glucagon-like peptide-1|glucose-dependent insulinotropic polypeptide|glucagon receptor activator therapies and dopaminergic signaling. While GIP stimulators are widely employed for addressing type 2 diabetes mellitus, their potential consequences on reward circuits, specifically influenced b… Read More